RecruitingNCT03717844
4
studies recruiting now
as of 7 Sept 2026
19
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
17 May 2024
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT06418477
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
RecruitingNCT06065852
National Registry of Rare Kidney Diseases
RecruitingNCT05283993
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Showing the 4 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Light chain deposition disease studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Light chain deposition disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Light chain deposition disease
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
2 approved treatments and 21 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Tafamidis (Vyndamax)Approved: Tafamidis Meglumine (Vyndaqel)
Phase 3Cyclophosphamide (Cyclophosphamide)
Phase 3Dexamethasone (Aeroseb-dex)
Phase 3Lenalidomide (Lenalidomide accord)
Phase 3Daratumumab (Daratumumab component of darzalex faspro)
Phase 3Anselamimab
Phase 3Birtamimab
Phase 2/3Doxycycline (Doxirobe)
Phase 2Amiodarone Hydrochloride (Amidox)
+ 13 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).